A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apremilast in Children from 5 to Less Than 18 Years of Age with Active Juvenile Psoriatic Arthritis (PEAPOD)

Principal Investigator

Dr Inga Turtsevich

Contact us

Email: childrensresearch@ouh.nhs.uk

IRAS number

1004177